[1]胡继红,赵学凌,李宏昆,等.TGF)、- β1、Serpine1、vWF、PF4在深静脉血栓患者血白细胞和血小板中的表达[J].介入放射学杂志,2013,(03):185-189.
 HU Ji? hong,ZHAO Xue? ling,LI Hong? kun,et al.The TGF-β1, serpine1, vHF and PF4 expression of leucocytes and platelets in patients with deep vein thrombosis[J].journal interventional radiology,2013,(03):185-189.
点击复制

TGF)、- β1、Serpine1、vWF、PF4在深静脉血栓患者血白细胞和血小板中的表达()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2013年03期
页码:
185-189
栏目:
血管介入
出版日期:
2013-03-25

文章信息/Info

Title:
The TGF-β1, serpine1, vHF and PF4 expression of leucocytes and platelets in patients with deep vein thrombosis
作者:
胡继红 赵学凌 李宏昆 吴雪梅 王 兵
Author(s):
HU Ji?蛳 hong ZHAO Xue?蛳 ling LI Hong?蛳 kun WU Xue?蛳 mei WANG Bing.
Department of Radiology and Department of Orthopaedics, the First Affiliated Hospital of Kunming Medical College, Kunming, Yunnan Province 650032, China.
关键词:
【关键词】 深静脉血栓转化生长因子-β1 纤溶酶原激活物抑制因子1 血管性血友病因子 血小板第4因子
文献标志码:
A
摘要:
【摘要】 目的 研究转化生长因子(TGF)- β1、纤溶酶原激活物抑制因子1(Serpine1)、血管性血友病因子(vWF)、血小板第4因子(PF4) mRNA在深静脉血栓患者血白细胞和血小板中的表达变化及在血栓形成中的作用。方法 将患者分为血栓形成组15例和无血栓形成组15例,另选正常对照组15例。采集患者血栓形成和不形成时相应状态的血液样本,提取血白细胞和血小板中总RNA,并反转录为cDNA,采用PCR和实时-PCR技术,检测TGF?蛳 β1、Serpine1、vWF、PF4 mRNA在各组中的表达。结果 PCR和实时-PCR的检测结果一致,TGF?蛳 β1、Serpine1、vWF、PF4 mRNA在血栓形成组中的表达明显高于无血栓形成组和正常对照组(P < 0.05),而在无血栓形成组和正常对照组间则差异无统计学意义(P > 0.05)。结论血白细胞和血小板中TGF?蛳 β1、Serpine1、vWF、PF4 mRNA表达上调可能在深静脉血栓形成中发挥了重要作用。

参考文献/References:

[1] 顾建平, 徐 克, 滕皋军. 下肢深静脉血栓形成介入治疗规范的专家共识[J]. 介入放射学杂志, 2011, 20: 505 ?蛳 510.[2] 李 炯, 唐 博. 静脉血栓栓塞生物标志物的研究进展[J]. 重庆医学, 2012, 41: 2326 ?蛳 2328.[3] Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis[J]. Blood Rev, 2009, 23: 225 ?蛳 229.[4] Schmittgen TD, Livak KJ. Analyzing real?蛳 time PCR data by the comparative C(T) method[J]. Nat Protoc, 2008, 3: 1101 ?蛳 1108.[5] Xu AG, Xu RM, Lu CQ, et al. Correlation of von willebrand factor gene polymorphism and coronary heart disease[J]. Mol Med Report, 2012, 6: 1107 ?蛳 1110.[6] van Galen KP, Tuinenburg A, Smeets EM, et al. Von willebrand factor deficiency and atherosclerosis[J]. Blood Rev, 2012, 26: 189 ?蛳 196.[7] Aidoudi S, Bikfalvi A. Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis[J]. Thromb Haemost, 2010, 104: 941 ?蛳 948.[8] Kowalska MA, Rauova L, Poncz M. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis[J]. Thromb Res, 2010, 125: 292 ?蛳 296.[9] Brogren H, Karlsson L, Andersson M, et al. Platelets synthesize large amounts of active plasminogen activator inhibitor 1[J]. Blood, 2004, 104: 3943 ?蛳 3948.[10] Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI?蛳 1[J]. Blood, 2010, 116: 113 ?蛳 121.[11] Akhter MS, Biswas A, Ranjan R, et al. Plasminogen activator inhibitor?蛳 1(PAI?蛳 1) gene 4G/5G promoter polymorphism is seen in higher frequency in the Indian patients with deep vein thrombosis[J]. Clin Appl Thromb Hemost, 2010, 16: 184 ?蛳 188.[12] 胡继红, 吴雪梅, 李兴国, 等. 转化生长因子 β1 和纤溶酶原激活物抑制因子1促进创伤性深静脉血栓形成的实验研究[J]. 介入放射学杂志, 2011, 20: 890 ?蛳 894.[13] Samarakoon R, Higgins SP, Higgins CE, et al. TGF?蛳 beta1?蛳 induced plasminogen activator inhibitor?蛳 1 expression in vascular smooth muscle cells requires pp60(c?蛳 src)/EGFR(Y845) and Rho/ROCK signaling[J]. J Mol Cell Cardiol, 2008, 44: 527 ?蛳 538.

备注/Memo

备注/Memo:
(收稿日期:2013-01-12)
更新日期/Last Update: